The manufacturers that market transcatheter aortic valve replacement (TAVR) systems in the US support the US Centers for Medicare and Medicaid Services' (CMS) new Medicare National Coverage Determination (NCD) for TAVR. They believe the new policy will help bring TAVR to patients that cannot access the procedure under the existing policy, created in 2012.
"We commend CMS on its thoughtful approach toward updating the TAVR policy,”Edwards Lifesciences Corp., which markets the Sapien line of TAVR systems, said. “Throughout the NCD process, Edwards emphasized...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?